Global Search | Novartis United States of America

Hide Filters

Showing 683 results

Media Release / Mar 21, 2013

New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies

-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1-- Gilenya is the first oral…
Media Release / Mar 21, 2013

New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Media Release / Feb 24, 2013

Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy

- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU)- CIU can be a serious, debilitating form of hives…
Media Release / Feb 24, 2013

Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Media Release / Feb 15, 2013

Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients

- Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation- Approval based on…
Media Release / Feb 15, 2013

Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
Media Release / Jan 23, 2013

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia

-- Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate1-- Patients with NTDT accumulate…
Media Release / Jan 23, 2013

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
Media Release / Dec 19, 2012

NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis

- Endpoints met in two Phase III trials, including substantial symptom relief in 84% of systemic juvenile idiopathic arthritis (SJIA) patients treated with ACZ885 in trial-11- SJIA patients treated…
Media Release / Dec 19, 2012

NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis

‹ Previous page
1
…
53
54
55
56
57
58
59
…
69
› Next page

Related News & Media